Novo Nordisk posts strong late-stage results for oral diabetes pill in children and teens

The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c

Practo reports surge in lifestyle disease awareness within Tier 2 cities, led by metabolic health searches

Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes

This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin

NewcelX and Eledon join forces to advance potential Type 1 diabetes cure

The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets

Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause

Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%

The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Biocon completes Rs. 4,150 crore equity fundraise through QIP

The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited